AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Rhea-AI Summary

AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 AFFIRM study of risankizumab (SKYRIZI) subcutaneous induction in adults with moderately to severely active Crohn's disease on March 2, 2026. Co-primary endpoints at week 12 met: CDAI clinical remission 55% vs 30% and endoscopic response 44% vs 14% versus placebo (both p<0.0001). Among 12-week responders who continued maintenance, 67% achieved clinical remission and 57% achieved endoscopic response at week 24. Safety was consistent with known profile; most common adverse events were upper respiratory tract infection, abdominal pain and arthralgia.

Positive

• CDAI clinical remission 55% at week 12 versus 30% placebo
• Endoscopic response 44% at week 12 versus 14% placebo
• Week 24 maintenance: 67% clinical remission among 12-week responders

Negative

• Most common adverse events: upper respiratory infection, abdominal pain, arthralgia
• Study enrolled predominantly treatment-refractory population (65%), affecting generalizability

News Market Reaction – ABBV

+0.94%

1 alert

+0.94% News Effect

On the day this news was published, ABBV gained 0.94%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

CDAI remission week 12: 55% vs 29.6% Endoscopic response week 12: 44% vs 14.3% AFFIRM sample size: N=289 (100 naïve, 189 prior failure) +5 more

8 metrics

CDAI remission week 12 55% vs 29.6% AFFIRM overall population, risankizumab SC vs placebo

Endoscopic response week 12 44% vs 14.3% AFFIRM overall population, risankizumab SC vs placebo

AFFIRM sample size N=289 (100 naïve, 189 prior failure) Phase 3 AFFIRM Crohn’s study population

Refractory population share 65% Patients with prior failure to ≥1 advanced therapy

Week 24 CDAI remission 67% Among clinical responders after 12 weeks induction + 12 weeks maintenance

Week 24 endoscopic response 57% Among clinical responders after induction + maintenance

Serious adverse events 0.5% vs 3.1% Risankizumab SC vs placebo during 12-week blinded period

Failed ≥2 advanced therapies 50% of refractory patients Subset within prior advanced therapy failure group

Market Reality Check

Price: $234.06 Vol: Volume 4,093,467 is below...

low vol

$234.06 Last Close

Volume Volume 4,093,467 is below the 20-day average of 7,223,348 (about 0.57x typical activity). low

Technical Trading above the 200-day MA with price at $232.16 versus 200-day MA of $212.30, and about 5% below the 52-week high of $244.81.

Peers on Argus

ABBV gained 3.29% while large-cap peers were mixed: JNJ +1.8%, LLY +3.22%, AZN +...

ABBV gained 3.29% while large-cap peers were mixed: JNJ +1.8%, LLY +3.22%, AZN +0.72% versus NVS -0.29% and NVO -0.24%. The move appears more company-specific than a broad sector rotation.

Previous Clinical trial Reports

5 past events · Latest: Jan 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 16	DLBCL Phase 3 data	Positive	-1.1%	Phase 3 EPCORE DLBCL-1 showed improved PFS but no OS benefit.
Oct 29	Vitiligo Phase 3 data	Positive	-1.1%	Upadacitinib met co-primary vitiligo endpoints with strong repigmentation rates.
Oct 20	RA head-to-head trial	Positive	+1.1%	RINVOQ outperformed HUMIRA in TNF-inhibitor inadequate responder RA patients.
Oct 06	Essential tremor Phase 2	Positive	-1.6%	ELATE trial met primary and secondary endpoints with known BOTOX safety.
Sep 26	Tavapadon NDA filing	Positive	+0.9%	NDA submission for tavapadon supported by positive Phase 3 TEMPO program.

Pattern Detected

Recent clinical trial headlines have often seen muted or negative next-day moves: 3 of the last 5 similar announcements were followed by share price declines despite generally positive data.

Recent Company History

Over the past six months, AbbVie has reported multiple positive clinical milestones across oncology, immunology and neurology. Events include Phase 3 data for epcoritamab in DLBCL on Jan 16, 2026, Phase 3 vitiligo results for RINVOQ on Oct 29, 2025, and a positive Phase 2 ELATE trial for BOTOX in essential tremor on Oct 6, 2025, plus an NDA submission for tavapadon in Parkinson’s on Sep 26, 2025. Despite these, the average next-day move around clinical-trial news has been about -0.34%, suggesting historically cautious price reactions to R&D updates.

Historical Comparison

-0.3% avg move · In the past year AbbVie’s clinical-trial headlines averaged a -0.34% next-day move. Today’s +3.29% r...

clinical trial

-0.3%

Average Historical Move clinical trial

In the past year AbbVie’s clinical-trial headlines averaged a -0.34% next-day move. Today’s +3.29% reaction to positive Crohn’s data is stronger than typical for this news type.

Clinical updates span multiple franchises: oncology (epcoritamab Phase 3), immunology (RINVOQ head-to-head and vitiligo Phase 3), neurology (BOTOX ELATE Phase 2), and Parkinson’s (tavapadon Phase 3–backed NDA). The new SKYRIZI Crohn’s Phase 3 data extend this progression into inflammatory bowel disease.

Market Pulse Summary

This announcement highlights strong Phase 3 AFFIRM results for subcutaneous SKYRIZI induction in mod...

Analysis

This announcement highlights strong Phase 3 AFFIRM results for subcutaneous SKYRIZI induction in moderately to severely active Crohn’s disease, with high rates of CDAI remission and endoscopic response at week 12 and sustained benefits at week 24. The study enrolled a largely treatment‑refractory population, and safety remained consistent with the known profile, with fewer serious adverse events than placebo. In context of AbbVie’s recent clinical milestones across multiple indications, investors may track upcoming full data presentations, regulatory steps, and how this regimen fits within the broader Crohn’s treatment landscape.

Key Terms

crohn's disease activity index (cdai), simple endoscopic score for crohn's disease (ses-cd), endoscopic response, janus kinase inhibitor (jaki), +2 more

6 terms

crohn's disease activity index (cdai) medical

"co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remission"

A numeric index that measures the severity of Crohn’s disease by combining patient symptoms, physical findings and basic lab data into a single score; higher numbers indicate worse disease. Investors watch it because drugmakers and regulators use changes in the CDAI as a clear, standardized “thermometer” of treatment benefit in clinical trials, which directly affects a therapy’s approval chances, labeling and commercial prospects.

simple endoscopic score for crohn's disease (ses-cd) medical

"decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) >50% from baseline"

A scoring system doctors use during an endoscopy to rate how active Crohn’s disease looks inside the bowel, based on simple findings like ulcers, inflammation, and narrowing. Investors should care because it’s a common clinical trial and regulatory endpoint that signals whether a treatment is visibly working in the gut — similar to a report card clinicians and regulators use to judge a drug’s real-world benefit and market potential.

endoscopic response medical

"and endoscopic responseb (44% vs. 14%; p<0.0001) at week 12 compared to placebo"

Endoscopic response is a measurable improvement in the appearance of internal tissue seen during an endoscopy, where a doctor uses a camera to look inside organs such as the colon or esophagus. For investors, it matters because this visible healing is often used as a key clinical trial outcome and regulatory benchmark that can signal whether a treatment is working, affecting a drug’s chances of approval and its commercial value—think of it as a before-and-after photo proving effectiveness.

janus kinase inhibitor (jaki) medical

"23% having failed ustekinumab and 12% having failed a Janus kinase inhibitor (JAKi)"

A janus kinase inhibitor (JAKi) is a type of medicine that blocks specific enzymes (JAKs) cells use to send growth and immune signals, effectively turning down the “volume” on certain immune responses. Investors care because JAKis are used to treat inflammatory diseases and some cancers; trial results, regulatory approvals, safety concerns, and patent status directly affect a drug maker’s sales potential and stock value.

double-blind medical

"Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. Not financial advice.

• In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI^®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo¹
• These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients¹
• The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, with no new safety risks observed¹

NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI^®) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD).¹

The AFFIRM study results show significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remission^a (55% vs. 30%; p<0.0001) and endoscopic response^b (44% vs. 14%; p<0.0001) at week 12 compared to placebo.¹ Among patients with clinical response^c after 12 weeks of risankizumab SC induction treatment followed by 12 weeks of maintenance, 67% achieved CDAI clinical remission at week 24 and 57% achieved endoscopic response at week 24.¹

This Phase 3 study enrolled a predominantly treatment-refractory population** (65%) with 50% of those patients having failed two or more advanced therapies and 23% having failed ustekinumab and 12% having failed a Janus kinase inhibitor (JAKi).¹

"This study evaluated a difficult-to-treat Crohn's disease patient population, including a majority with a prior failure to advanced therapy, and these data reinforce risankizumab as a leading, effective treatment for patients," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "The level of endoscopic response is a particularly meaningful achievement for Crohn's disease patients; and for AbbVie, these results underscore our continued innovation and research to raise the standard of care."

AFFIRM Phase 3 Co-Primary Endpoints Results at Week 12
	Overall Population  (N=289)		Advanced Therapy Naïve*  (N=100)		Prior Advanced Therapy Failure**  (N=189)
Proportion of patients	PBO	RZB SC	PBO	RZB SC	PBO	RZB SC
CDAI Clinical Remissiona	29.6 %	55 %	27.3 %	73.1 %	30.8 %	45.2 %
Endoscopic Responseb	14.3 %	44 %	15.2 %	61.2 %	13.8 %	34.7 %
RZB= risankizumab; PBO=placebo

*	Defined as patients without prior advanced therapy failure.1
**	Defined as patients with prior failure to at least one advanced therapy for CD.1
a	Defined as Crohn's Disease Activity Index (CDAI) <150 at week 12.1
b	Defined as decrease in Simple Endoscopic Score for Crohn's disease (SES-CD) >50% from baseline or for patients with isolated ileal disease and a baseline SES-CD of 4, at least a 2-point reduction from baseline, as scored by blinded central reviewer at week 12.1
c	Defined as at least a 100-point reduction from baseline in CDAI.1

"Crohn's disease is a complex, often debilitating condition that affects far more than a patient's digestive health, disrupting work, relationships and daily life," said Millie D. Long, M.D., MPH, chief, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, and lead investigator of the AFFIRM study. "These high endoscopic response rates across populations, in particular among those who have not failed an advanced therapy, demonstrate the potential of subcutaneous induction risankizumab as an effective therapy for Crohn's disease."

During the 12-week, double-blind, placebo-controlled period, the safety profile of risankizumab SC was consistent with the safety profile observed in Crohn's disease with no new safety risks observed. The most common adverse events observed among patients receiving risankizumab were upper respiratory tract infection, abdominal pain and arthralgia. Serious adverse events occurred in 0.5% of patients in the risankizumab SC group compared to 3.1% in the placebo group.¹

Full results will be published in an upcoming medical journal and shared at future medical congresses.

About Crohn's Disease
Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, most commonly in the area between the small intestine (ileum) and the colon, causing persistent diarrhea and abdominal pain.^2,3 It is a progressive disease, meaning it gets worse over time and may lead to life-threatening complications or surgery.^4,5 Because the signs and symptoms of Crohn's disease are unpredictable, it causes a significant burden on people living with the disease—not only physically but also emotionally and economically.⁶

About the AFFIRM Study¹ 
AFFIRM is a global, Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of risankizumab subcutaneous (SC) as an induction treatment in adult patients with moderately to severely active Crohn's disease. Co-primary endpoints were percentage of participants with CDAI Clinical Remission (CDAI < 150) and percentage of participants with endoscopic response at week 12. A total of 289 patients were randomized in a 2:1 ratio to risankizumab SC or placebo. Key demographics and baseline characteristics were generally balanced between the risankizumab SC and placebo groups; 65% had failed advanced therapies for the treatment of CD before. The study consists of three treatment periods: a placebo-controlled Period A (baseline to week 12) to evaluate the efficacy and safety of risankizumab SC induction treatment, an extended Period B (week 12 to 24) where patients receive blinded or open-label treatments based on their clinical response at week 12, and a 52-week open-label extension Period C where all patients receive the approved risankizumab maintenance treatment.¹ More information on this trial can be found at www.clinicaltrials.gov (NCT06063967).⁷

About SKYRIZI^® (risankizumab)
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.⁸ SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.^8,9

SKYRIZI^® (risankizumab-rzaa) U.S. Uses and Important Safety Information⁸

Indications

SKYRIZI is a prescription medicine used to treat adults with:

• moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
• active psoriatic arthritis.
• moderate to severe Crohn's disease.
• moderate to severe ulcerative colitis.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SKYRIZI^® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the    following symptoms of a serious allergic reaction:
• fainting, dizziness, feeling    lightheaded (low blood pressure)
• swelling of your face, eyelids, lips,    mouth, tongue, or throat   • trouble breathing or throat tightness
• chest tightness
• skin rash, hives   • itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

–        fever, sweats, or chills               –        cough       –        shortness of breath –        blood in your mucus           (phlegm)

–        muscle aches –        warm, red, or painful           skin or sores on your           body different from           your psoriasis                         –        weight loss

–        diarrhea or stomach           pain –        burning when you           urinate or urinating           more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"
• have an infection that does not go away or that keeps coming back.
• have TB or have been in close contact with someone with TB.
• have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
• become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?
SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

This is the most important information to know about SKYRIZI. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more. 

Please click here for the Full Prescribing Information and Medication Guide.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

1. AbbVie. Data on file ABVRRTI82775
2. Crohn's & Colitis Foundation. The facts about inflammatory bowel diseases. Crohn's & Colitis Foundation. Published November 2014. Accessed February 23, 2026. https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf
3. Mayo Clinic. Crohn's disease - Symptoms and causes. Mayo Clinic. Accessed February 23, 2026. https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304
4. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016 Mar;22(3 Suppl):s51-60.
5. Kaplan G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150.
6. Gajendran M, et al. A comprehensive review and update on Crohn's disease. Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001.
7. A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. (AFFIRM). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT06063967. Accessed February 23, 2026.
8. SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.; 2025.
9. SKYRIZI. Summary of Product Characteristics. AbbVie. Accessed February 23, 2026.

Global Media: Giovanna Chandler giovanna.chandler@abbvie.com   U.S. Media:  Stephanie Tennessen  stephanie.tennessen@abbvie.com

Investors: Liz Shea liz.shea@abbvie.com

 

View original content:https://www.prnewswire.com/news-releases/abbvie-announces-positive-topline-results-from-phase-3-affirm-study-evaluating-skyrizi-risankizumab-subcutaneous-induction-in-patients-with-crohns-disease-302700227.html

SOURCE AbbVie

FAQ

What did AbbVie (ABBV) announce about AFFIRM Phase 3 risankizumab results on March 2, 2026?

AbbVie announced positive topline Phase 3 AFFIRM results showing risankizumab SC met co-primary endpoints at week 12. According to the company, CDAI clinical remission was 55% vs 30% and endoscopic response was 44% vs 14% versus placebo (both p<0.0001).

How effective was risankizumab (SKYRIZI) SC induction in Crohn's disease in ABBV's AFFIRM trial?

Risankizumab SC induction showed superior efficacy versus placebo at week 12 on key endpoints. According to the company, CDAI remission was 55% and endoscopic response was 44% compared with placebo values of 30% and 14% respectively.

What were the week 24 maintenance outcomes reported by AbbVie (ABBV) after risankizumab induction?

Among patients with clinical response after 12 weeks, many maintained benefit at week 24. According to the company, 67% achieved CDAI clinical remission and 57% achieved endoscopic response at week 24 following maintenance treatment.

What safety findings did AbbVie report for risankizumab SC induction in the AFFIRM study (ABBV)?

Safety for risankizumab SC was consistent with its known profile with no new risks observed. According to the company, common adverse events included upper respiratory tract infection, abdominal pain, and arthralgia; serious adverse events were 0.5% versus 3.1% for placebo.

Which Crohn's disease patients were included in AbbVie's AFFIRM trial for risankizumab (ABBV)?

AFFIRM enrolled adults with moderately to severely active Crohn's disease, including many refractory cases. According to the company, 65% were treatment-refractory, with 50% of those failing two or more advanced therapies.